echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > SMART researchers discover unique lysin that kills deadly multidrug-resistant bacteria

    SMART researchers discover unique lysin that kills deadly multidrug-resistant bacteria

    • Last Update: 2022-03-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    • Lysin is an enzyme produced by bacteriophage that has shown potential as an alternative to antibiotics, especially against drug-resistant bacteria

    • Discovery of Abp013 will help researchers to design lysins with better antibacterial efficacy, especially against multidrug-resistant bacteria

    • As bacterial infections such as pneumonia and meningitis claim more lives each year due to growing resistance to antibiotics, the development of new alternatives to fungicides is critical

    SINGAPORE - Researchers from the Interdisciplinary Research Group (IRG) on Antimicrobial Resistance at the MIT Alliance for Research and Technology (SMART), together with collaborators at Nanyang Technological University, have identified a new bacteriophage lysin — —Abp013, which can be used as an alternative antimicrobial agent against two of the most deadly bacteria: Acinetobacter baumannii and Klebsiella pneumoniae


    Lysobacteria - enzymes produced by bacteriophages - show great potential as a new class of antibacterial agents, as their properties allow them to rapidly and directly attack key structural components of bacterial cell walls and in the process reduce bacterial resistance.


    Over the past few decades, the inappropriate and widespread use of antibiotics has led to the emergence of antimicrobial resistance—a phenomenon in which bacterial strains develop mechanisms to become resistant to drugs designed to kill them


    "Antibacterial resistance remains a growing threat to humanity, with an increase in the number of people dying from superbug infections each year


    Lysin is very effective against Gram-positive bacteria - Gram-positive bacteria do not have an outer lipid membrane and are therefore easily killed by lysin


    In a paper titled "A novel bacteriophage Lysin Abp013 against Acinetobacter baumannii" published in the medical journal Antibiotics, the SMART AMR team reveals their differences in Abp013's ability to efficiently acquire and kill various bacterial strains found


    Acinetobacter baumannii and Klebsiella pneumoniae are superbugs that cause a variety of potentially life-threatening infections, such as pneumonia and meningitis, especially in sick and immunocompromised populations


    Abp013 is the first Gram-negative lysin discovered to exhibit host selectivity


    In the future, the researchers will further study the crystal structure of this novel lysine and understand its unique underlying mechanism


    SMART AMR has been developing custom targeting methods for bacteria using lysogens, and these efforts have received early support from the SMART Innovation Center


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.